Impact of deranged B cell subsets distribution in the development of HCV-related cirrhosis and HCC in type two diabetes mellitus

Fadwa A. Abdelwahab¹, Khaled M. Hassanein¹, Helal F. Hetta¹, Helal F. Hetta²,³, Mohamed O. Abdelmalek⁴, Asmaa M. Zahran⁵ & Omnia El-Badawy²*

Type II diabetes (T2D) may worsen the course of hepatitis C virus infection with a greater risk of liver cirrhosis (LC) and hepatocellular carcinoma (HCC). In chronic viral infections, the deranged B cell subset signifies uncontrolled disease. The study aimed to verify the relation between B cell subsets’ distribution and liver disease progression in chronic hepatitis C (CHC) patients with T2D. A total of 67 CHC patients were divided into two groups; 33 non-diabetic and 34 with T2D. Each group was subdivided into CHC-without LC or HCC (N-CHC), CHC-with LC (CHC-LC), and CHC-with HCC (CHC-HCC). Twenty-seven healthy individuals also participated as controls. Flow cytometry was used to analyze CD19⁺ B cell subsets based on the expression of CD24 and CD38. CD19⁺CD24hiCD38hi immature/transitional B cells elevated in diabetic than non-diabetic patients. In diabetic patients, while CD19⁺CD24⁺CD38⁻ primarily memory B cells were higher in CHC-N and CHC-HCC groups than LC with a good predictive accuracy of LC, the opposite was observed for CD19⁺CD24⁻CD38⁻ new memory B cells. Only in diabetic patients, the CD19⁺CD24hiCD38hi naïve mature B cells were high in CHC-HCC patients with good prognostic accuracy of HCC. Merely in diabetic patients, several correlations were observed between B cell subsets and liver function. Immature/transitional B cells increase remarkably in diabetic CHC patients and might have a role in liver disease progression. Memory and Naïve B cells are good potential predictors of LC and HCC in diabetic CHC patients, respectively. Further studies are needed to investigate the role of the CD19⁺CD24⁻CD38⁻ new memory B cells in disease progression in CHC patients.

Hepatitis C virus (HCV) is the leading cause of chronic liver disease that can eventually lead to liver cirrhosis (LC) and hepatocellular carcinoma (HCC)¹. Type 2 diabetes (T2D) is the most familiar form of diabetes, accounting for above 90% of all diabetic patients². T2D is a well-known cofactor that may worsen the outcomes of HCV infection. It is associated with a greater risk of cirrhosis and HCC development, entailing poor prognosis in patients with and without cirrhosis³,⁴. Hereafter, studying the immunopathogenesis and looking for new and specific immunological markers to predict the progression of chronic hepatitis C (CHC) to LC and HCC in T2D patients has become of great scientific interest.

Generally, B cells play a central role in obesity, insulin resistance, and glucose intolerance. They promote inflammation by activating proinflammatory T cells and secretion of proinflammatory cytokines, including IL-6 and TNF-α. B cells may induce insulin resistance by the activation of Th1 and CD8⁺ T cells and the release of pathogenic IgG antibodies⁶,⁷. These pathogenic antibodies aggravate the metabolic disease via activation of immune cells, mostly Fc-dependent activation of macrophages inducing secretion of proinflammatory cytokines. Thus, B cells are prospective promising therapeutic targets for T2D⁸.

Five main B cell subsets can be identified in the peripheral blood based on the expression of the two developmental regulation markers CD24 and CD38, in conjunction with the B cell lineage marker CD19. Based on these surface markers, B cell populations include the immature/transitional B cells (CD19⁺CD24hiCD38hi),...
naive mature B cells which have not encountered an antigen (CD19+CD24intCD38int), antibody-secreting plasmablasts (CD19+CD24+CD38+), primarily memory B cells (CD19+CD24-CD38-) and new memory (CD19+CD24+CD38+) B cells. Moreover, immune regulation by CD24+CD38+ B cells was associated with promising clinical outcome in patients with chronic inflammatory diseases16, and IL-10 producing Bregs have been proposed to have a role in the pathogenesis of hepatitis B virus infection17.

In chronic viral infections as human immunodeficiency virus (HIV), deranged B cell functions and subset distribution signifies uncontrolled disease18. The levels of immature transitional B cells were shown to be related to some conditions with humoral immune deficiency, including HIV infection19. HCV infection is associated with increased B cell activation and proliferation with increased risk of autoimmune and B cell lymphoproliferative disorders20-24. Few studies have investigated the alteration in B cell subsets in patients with HCV25,26, and the role of the different B-cell subsets in chronic HCV infection is incompletely understood. To date, as far as we know, no one has addressed the relations of B cell subsets with the liver disease progression in CHC patients with T2D. Thus, the study aimed to verify the possibility of an association between the different B cell subsets distribution and liver disease progression in CHC patients with T2D.

Materials and methods

Study Subjects. A total of 67 CHC patients presented to Al Rajhi Liver Hospital, Assiut, Egypt (tertiary care university hospital) were enrolled in this case–control study. Twenty-seven age and sex-matched healthy individuals also participated as controls. We excluded patients treated with interferon, ribavirin, or immunomodulating agents, co-infected with hepatitis A, B viruses, or human immunodeficiency virus, those having alcohol or drug-induced liver diseases, or those with positive anti-schistosomal antibodies. The Ethics Committee of the Faculty of Medicine, Assiut University, reviewed and accepted the research proposal (IRB no. 17100797). All methods were performed in full accordance with the regulations of Assiut University Faculty of Medicine. All participants provided informed consent before sharing in the study.

Patients were divided into two main groups; 33 non-diabetic CHC patients and 34 CHC patients with T2D. Each group was further subdivided according to the stage of liver disease into three sub-groups; CHC-without LC or HCC (N-CHC), CHC-with LC (CHC-LC), and CHC-with HCC (CHC-HCC). CHC patients were diagnosed by fluctuations of serum transaminases levels for more than six months, positive HCV antibodies, and serum HCV-RNA. The diagnosis of LC was established by the typical imaging criteria in abdominal triphasic computed tomography or abdominal dynamic MRI with diffusion with or without raised serum alpha-fetoprotein. Diabetes mellitus type II was identified by finding: fasting blood glucose (FBG) ≥ 126 mg/dL (7 mmol/L); (fasting is defined as no caloric intake for at least 8 h), Hemoglobin A1c (HbA1c) ≥ 6.5%, Two-hour plasma glucose level ≥ 200 mg/dL (11.1 mmol/L) during a 75-g oral glucose tolerance test or random plasma glucose ≥ 200 mg/dL (11.1 mmol/L) in a patient with classic hyperglycemia symptoms (polyuria, polydipsia, polyphagia, and weight loss) or hyperglycemic crisis27.

Flow cytometry analysis. Flow cytometry was accomplished by fluorescence-activated cell sorter (FACS Calibur, Becton Dickinson, USA) using a set of fluorochrome-labeled monoclonal antibodies against B cell surface markers (APC-conjugated anti-CD19, FITC-conjugated anti-CD24, and PE-conjugated anti-CD38). All monoclonal antibodies were obtained from R&D Systems, USA.

One hundred microliters of heparinized blood were transferred into a clean tube, and RBCs lysing solution was added. The pellet after centrifugation was washed with phosphate-buffered saline (PBS). Samples were centrifuged again, and ten microliters of each of the monoclonal antibodies (CD19, CD 24, and CD38) were added to the pellet. The mixture was incubated for 15 min at 4 °C in the dark. Appropriate isotype controls were processed in a parallel manner without adding B cell monoclonal antibodies. A minimum of 50,000 events was collected for each sample analysis. Cell Quest software (BD, USA) was used for flow cytometric analysis. Through the forward scatter (FSC)/side scatter (SSC) dot plot, the PBMCs population was selected to analyze CD19 expression. After that, the CD19+ B cells were selected for further analysis of B cell subsets based on the expression of CD24 and CD38. CD19+CD24hiCD38hi were considered as immature/transitional B cells, CD19+CD24+CD38+ are naive mature B cells, CD19+CD24-CD38- are primarily memory B cells, CD19+CD24+CD38+ are plasmablasts and CD19+CD24-CD38- are new memory B cells. The different B cell subsets were expressed as percentages within the CD19+ lymphocytes (Fig. 1).

Statistical analysis. The data were tested for normality using the Anderson–Darling test and for homogeneity of variances before further statistical analysis. Categorical variables were described by number and percent, whereas continuous variables were described by the mean and standard deviation or standard error (Mean, SD or SE). Between groups difference was investigated by the multivariate analysis of covariance (MANCOVA) with age and sex as covariates. A two-tailed p < 0.05 was considered statistically significant. Pearson correlation was applied to evaluate the association between variables. A receiver operating characteristic (ROC) curve was used to determine the cut-off value, sensitivity, specificity, and accuracy of each B cell subset in the prediction of cirrhosis and HCC. Statistical analysis was performed by the SPSS version 20.0 software (IBM, USA).
Results

Patients’ characteristics. The study encompassed 36 males (53.7%) and 31 females (46.3%). Their ages ranged from 31 to 67 years, with a mean age of 59.4 ± 9 years. Table 1 demonstrates the characteristics of the different patients’ groups. All patients had elevated levels of ALT and AST, with the highest levels observed in the diabetic CHC-HCC patients. Bilirubin levels increased in all groups, especially the cirrhotic patients. Similarly, the lowest levels of total protein, albumin, and A/G ratio were detected in cirrhotic patients. Marked affection of prothrombin time and concentration and international normalized ratio (INR) was seen in the CHC-LC and CHC-HCC patients. The diabetic CHC-N patients have shown the highest HCV load among the studied groups. The most elevated fasting plasma glucose (FPG) level among the studied groups was also observed in the diabetic patients compared with the non-diabetic (n = 34) patients in any measured laboratory parameters. Of all HCC patients, 13 had Child–Pugh score A, eight had score B, and one had score C.

Analysis of CD19+ B cell subsets in chronic hepatitis C patients with respect to T2D. As presented in Table 2, regardless of the degree of liver affection, the percentages of CD19+CD24hiCD38hi Immature/transitional (from CD19+ B cells) in both the diabetic and the non-diabetic groups were higher than that in the healthy controls, but this difference was only significant in the diabetic group (mean, 13.6 ± 1, 10.7 ± 1 vs. 7.8 ± 1, p = 0.001, p = 0.1, respectively). They were also higher in diabetic patients compared with the non-dia-
betic patients \((p=0.03)\). Although the highest levels of CD19+CD24+CD38− naïve mature B cells (from CD19+ B cells) were detected in diabetic patients, no statistically significant differences were observed among the three groups.

The percentages of CD19+CD24+CD38− primarily memory B cell subset (from CD19+ B cells) in both the diabetic and the non-diabetic groups were considerably raised than that in the healthy controls (mean, 23.8 ± 2, 30.2 ± 2 vs. 14.3 ± 3, \(p=0.02\), \(p<0.0001\), respectively). However, the level of this subset of B cells was considerably lower in diabetic patients when compared with non-diabetic patients \((p=0.04)\). On the contrary, a remarkable decrease was observed in the level of CD19+CD24−CD38− new memory B cells in both the diabetic and non-diabetic groups than the healthy controls (mean, 14.3 ± 3, 14 ± 3 vs. 32.2 ± 4, \(p<0.0001\) for both), yet with no significant differences between the diabetic and non-diabetic groups \((p=0.96)\).

On the other hand, levels of CD19+CD24−CD38+ plasmablasts were significantly elevated in both the diabetic and non-diabetic patients than healthy controls (mean, 1.7 ± 0.1, 1.8 ± 0.1 vs. 1 ± 0.2, \(p=0.007\), \(p=0.003\), respectively), with no difference between the diabetic and non-diabetic patients \((p=0.6)\).

Characterization of CD19+ B cell population in chronic hepatitis C patients with respect to the degree of liver affection. As shown in Table 3, irrespective of the presence of diabetes, the percentage of CD19+CD24hiCD38hi Immature/transitional B cells (from CD19+ B cells) was elevated in the CHC-N, CHC-LC and CHC-HCC patients than the healthy controls (mean, 11.2 ± 1, 13.2 ± 1, 12.5 ± 1 vs. 7.7 ± 1, \(p=0.07\), \(p=0.007\), \(p=0.02\), respectively). Meanwhile, no statistically considerable differences were observed among the three groups of patients. On the other hand, the percentage of CD19+CD24lowCD38low naïve mature B cells (from CD19+ B cells) was elevated in the CHC-HCC patients in comparison with both the control (mean, 48.4 ± 2 vs. 42.5 ± 2, \(p=0.07\)) and the CHC-N group (mean, 48.4 ± 2 vs. 41.4 ± 2, \(p=0.01\)).

In the same way, an elevation of the frequency of CD19+CD24+CD38+ primarily memory B cell subset (from CD19+ B cells) was observed in the CHC-N, CHC-LC, and CHC-HCC patients compared with the healthy controls (mean, 29.4 ± 3, 21.5 ± 3, 29 ± 3 vs. 14.6 ± 3, \(p=0.001\), \(p=0.1\), \(p=0.002\), respectively), but with no significant
Figure 3. (A) Correlations of CD19⁺CD24intCD38int naïve mature B cells with prothrombin time and correlations of CD19⁺CD24⁺CD38⁻ primarily memory B cells with (B) prothrombin concentration and (C) INR in the diabetic CHC patients.

Figure 4. Receiver operating characteristic (ROC) curve of (A) CD19⁺CD24⁺CD38⁻ primarily memory B cells and (B) CD19⁺CD24intCD38int naïve mature B cells, for prediction of liver cirrhosis and hepatocellular carcinoma, respectively, in diabetic chronic hepatitis C patients.
difference between CHC-LC patients and control group. Moreover, its level was raised in both the CHC-N and CHC-HCC patients than in the CHC-LC patients ($p = 0.04$, for both groups).

On the contrary, the frequency of $CD19^{+}CD24^{−}CD38^{−}$ new memory B cells (from $CD19^{+}$ B cells) decreased in the CHC-N, CHC-LC, and CHC-HCC patients compared with the healthy controls (mean, 15 ± 3, 17 ± 3, 10 ± 3 vs. 32 ± 4, $p = 0.001$, $p = 0.005$, $p < 0.0001$, respectively) and was somewhat lower in both the CHC-N and CHC-HCC patients than in the CHC-LC patients.

Also, the frequencies of $CD19^{+}CD24^{−}CD38^{+}$ plasmablasts in the CHC-N, CHC-LC, and CHC-HCC groups were higher than that in the control group (mean, 1.7 ± 0.1, 1.8 ± 0.1, 1.8 ± 0.2 vs. 1 ± 0.2, $p = 0.01$, $p = 0.006$, $p = 0.008$, respectively), with no statistically significant differences among the three groups of patients.

### Analysis of the $CD19^{+}$ B cell subsets in CHC patients with different degrees of liver affection with respect to T2D.

Results are shown in Table 4.
Table 3. CD19+ B cell subsets in chronic hepatitis C patients with respect to the degree of liver affection. (%): the percentage was calculated from CD19+ B cells. CHC-N: chronic hepatitis C with no cirrhosis or hepatocellular carcinoma, CHC-LC: chronic hepatitis C with liver cirrhosis, CHC-HCC: chronic hepatitis C with hepatocellular carcinoma. Results expressed as mean ± standard error. Multivariate analysis of covariance (MANCOVA) with age and sex as covariates Significant p-value is <0.05 (bold). p1: CHC-N vs. Control p2: CHC-LC vs. Control p3: CHC-HCC vs. Control. p4: CHC-N vs. CHC-LC p5: CHC-N vs. CHC-HCC p6: CHC-LC vs. CHC-HCC.

| B cell subsets (%) | Control n = 27 | CHC-N n = 20 | CHC-LC n = 24 | CHC-HCC n = 23 | p-values | p1 | p2 | p3 | p4 | p5 | p6 |
|--------------------|---------------|--------------|---------------|---------------|----------|-----|-----|-----|-----|-----|-----|
| CD19+CD24hiCD38hi B cells | 7.7 ± 2 | 11.2 ± 1 | 13.2 ± 1 | 12.5 ± 1 | 0.07 | 0.007 | 0.02 | 0.2 | 0.5 | 0.7 |
| CD19+CD24hiCD38hi B cells | 42.5 ± 2 | 41.4 ± 2 | 45.6 ± 2 | 48.4 ± 2 | 0.7 | 0.3 | 0.07 | 0.1 | 0.01 | 0.3 |
| CD19+CD24+CD38− B cells | 14 ± 3 | 29.4 ± 3 | 21.5 ± 3 | 29 ± 3 | 0.001 | 0.1 | 0.002 | 0.04 | 0.9 | 0.04 |
| CD19+CD24+CD38− B cells | 1 ± 0.2 | 1.7 ± 0.1 | 1.8 ± 0.1 | 1.8 ± 0.2 | 0.01 | 0.006 | 0.008 | 0.7 | 0.7 | 0.9 |
| CD19+CD24+CD38− B cells | 32 ± 4 | 15 ± 3 | 17.3 ± 3 | 10 ± 3 | 0.001 | 0.005 | <0.0001 | 0.6 | 0.3 | 0.1 |

Analysis of CD19+CD24hiCD38hi Immature/transitional B cells. In the diabetic patients alone, the frequencies of Immature/transitional B cells in the three diabetic groups (CHC-N, CHC-LC and CHC-HCC) were significantly higher than the controls (mean, 1.2 ± 0.3, 1.5 ± 1, 1.3 ± 2 vs. 7.7 ± 2, p = 0.046, p = 0.001, p = 0.02, respectively). The highest level of Immature/transitional B cells was observed in cirrhotic patients but with no significant differences from the other two groups of patients. In the meantime, no significant differences were detected among the three non-diabetic groups.

Analysis of CD19+CD24hiCD38hi naïve mature B cells. In the diabetic groups, the highest level of CD19+CD24hiCD38hi B cells was seen in the CHC-HCC patients (52.5 ± 3), in comparison with the controls (mean, 31.2 ± 3, 27.9 ± 3 vs. 14.3 ± 3, p<0.0001, respectively) and the CHC-N group (p = 0.002). Meanwhile, no significant differences were observed in the frequencies of CD19+CD24hiCD38hi B cells among the three non-diabetic groups and the control group.

Analysis of CD19+CD24+CD38− primarily memory B cells. In the diabetic patients, the frequency of CD19+CD24+CD38− B cells notably increased in the CHC-N and CHC-HCC patients compared with the controls (mean, 31.2 ± 3, 27.9 ± 3 vs. 14.3 ± 3, p<0.0001, p = 0.004, respectively). In contrast, in the non-diabetic patients, the levels of CD19+CD24+CD38− primarily memory B cells were significantly high in the three patients’ groups (CHC-N, CHC-LC, and CHC-HCC) in comparison with the controls (mean, 26.6 ± 3, 33.4 ± 4, 31.6 ± 4 vs. 14.3 ± 3, p<0.0001, p = 0.001, respectively), with no significant differences among the three non-diabetic groups of patients.

Analysis of CD19+CD24+CD38− new memory B cells. Level of CD19+CD24+CD38− new memory B cells (from CD19+ B cells) significantly decreased in the CHC-N, CHC-LC and CHC-HCC groups compared with the healthy controls in both the the diabetic patients ((p = 0.002, p = 0.03 and p <0.0001, respectively), and the non-diabetic patients (p = 0.02, p = 0.005 and p = 0.001, respectively). But no significant differences were observed between the patients’ groups.

Analysis of CD19+CD24+CD38− plasmablasts. In the diabetic groups, this B cell subset was only presenting higher levels in the CHC-LC group than the healthy controls (p = 0.007). On the contrary, the frequencies of CD19+CD24+CD38− plasmablasts raised in the three non-diabetic groups (CHC-N, CHC-LC and CHC-HCC) compared with the controls (mean, 1.8 ± 0.2, 1.9 ± 0.2, 1.9 ± 0.2 vs. 1 ± 0.2, p = 0.03, p = 0.05, p = 0.007, respectively), with no significant differences among the three non-diabetic groups of patients.

Evaluation of the associations between the different B cell subsets and the laboratory findings with respect to T2D. Several significant associations were detected, especially among the diabetic patients.

CD19+CD24hiCD38hi Immature/transitional B cells. As shown in Fig. 2, in the diabetic patients, immature/transitional B cells revealed direct associations with both total and direct bilirubin levels (r = 0.5, p = 0.004 and r = 0.4, p = 0.02, respectively) and inverse relations with both albumin and prothrombin concentration (r = −0.3, p = 0.03 and r = −0.3, p = 0.03, respectively). Additionally, these cells had direct relation with the Child–Pugh score in the non-diabetic and diabetic CHC-HCC patients (r = 0.7, p = 0.03 and r = 0.5, p = 0.04, respectively). Moreover, immature/transitional B cells were the only cells showing direct relation with age (r = 0.3, p = 0.04) in the diabetic patients alone.

CD19+CD24hiCD38hi naïve mature B cells and CD19+CD24+CD38− plasmablasts. As shown in Fig. 3, an association was observed between CD19+CD24hiCD38hi B cells and prothrombin time (r = 0.4, p = 0.001). On the other hand, no significant associations were observed in the diabetic and non-diabetic groups of patients between CD19+CD24+CD38− plasmablasts and any measured laboratory parameters.
Table 4. CD19+ B cell subsets in chronic hepatitis C patients with different degrees of liver affection in relation to diabetes mellitus. (%) the percentage was calculated from CD19+ B cells. CHC-N chronic hepatitis C with no cirrhosis or hepatocellular carcinoma, CHC-LC chronic hepatitis C with liver cirrhosis, CHC-HCC chronic hepatitis C with hepatocellular carcinoma. Results expressed as mean ± standard error. Multivariate analysis of covariance (MANCOVA) with age and sex as covariates, Significant p-value is <0.05 (bold). p1: CHC-N vs. Control p2: CHC-LC vs. Control p3: CHC-HCC vs. Control. p4: CHC-N vs. CHC-LC p5: CHC-N vs. CHC-HCC p6: CHC-LC vs. CHC-HCC.

| B cell subsets (%) | Control n = 27 | CHC-N n = 10 | CHC-LC n = 13 | CHC-HCC n = 11 | p values | p1 | p2 | p3 | p4 | p5 | p6 |
|--------------------|----------------|-------------|---------------|----------------|----------|----|----|----|----|----|----|
| CD19+CD24−CD38− B cells | 7.7 ± 2 | 12.3 ± 2 | 15.1 ± 1 | 13 ± 2 | 0.046 | 0.001 | 0.02 | 0.2 | 0.7 | 0.4 |
| CD19+CD24−CD38− B cells | 42.7 ± 2 | 40.6 ± 3 | 47.3 ± 2 | 52.5 ± 3 | 0.6 | 0.2 | 0.007 | 0.05 | 0.002 | 0.1 |
| CD19+CD24+CD38− B cells | 14.3 ± 3 | 31.2 ± 3 | 14.6 ± 3 | 27.9 ± 3 | <0.0001 | 0.9 | 0.004 | <0.0001 | 0.5 | 0.004 |
| CD19+CD24−CD38+ B cells | 1 ± 0.2 | 1.7 ± 0.2 | 1.9 ± 0.2 | 1.6 ± 0.2 | 0.06 | 0.007 | 0.07 | 0.5 | 0.9 | 0.4 |
| CD19+CD24−CD38+ B cells | 32.3 ± 4 | 13 ± 4 | 19.8 ± 4 | 8.6 ± 4 | 0.002 | 0.03 | <0.0001 | 0.3 | 0.5 | 0.06 |

Non-diabetic

| B cell subsets (%) | Control n = 27 | CHC-N n = 10 | CHC-LC n = 11 | CHC-HCC n = 12 | p values | p1 | p2 | p3 | p4 | p5 | p6 |
|--------------------|----------------|-------------|---------------|----------------|----------|----|----|----|----|----|----|
| CD19+CD24−CD38− B cells | 7.7 ± 2 | 10.4 ± 2 | 10.2 ± 2 | 11.6 ± 2 | 0.2 | 0.3 | 0.1 | 0.9 | 0.6 | 0.6 |
| CD19+CD24−CD38− B cells | 42.7 ± 2 | 42.7 ± 3 | 42.6 ± 3 | 43.4 ± 3 | 0.98 | 0.99 | 0.98 | 0.98 | 0.9 | 0.9 |
| CD19+CD24+CD38− B cells | 14.3 ± 3 | 26.6 ± 3 | 33.4 ± 4 | 31.6 ± 4 | 0.009 | <0.0001 | 0.001 | 0.2 | 0.3 | 0.7 |
| CD19+CD24+CD38− B cells | 1 ± 0.2 | 1.8 ± 0.2 | 1.9 ± 0.2 | 1.9 ± 0.2 | 0.03 | 0.05 | 0.007 | 0.9 | 0.6 | 0.5 |
| CD19+CD24−CD38+ B cells | 32.3 ± 4 | 17.5 ± 4 | 12.8 ± 5 | 11 ± 5 | 0.02 | 0.005 | 0.001 | 0.5 | 0.3 | 0.8 |

CD19+CD24+CD38− primarily memory and CD19+CD24+CD38− new memory B cells. As shown in Fig. 3, CD19+CD24+CD38− B cells have shown direct association with prothrombin concentration and albumin level (r = 0.3, p = 0.048 and r = 0.3, p = 0.05, respectively) and inverse relation with INR (r = -0.4, p = 0.02). Conversely, no significant correlations were detected between the level of CD19+CD24+CD38− new memory B cells and any of the laboratory findings in both the diabetic and non-diabetic patients.

Evaluation of the different B cell subsets as probable predictors of cirrhosis and HCC in CHC patients. The Receiver Operating Characteristics (ROC) curve has been used to evaluate the accuracy of using the blood levels of different B cell subsets as potential predictors of developing LC and HCC in CHC patients. None of the B cell subsets showed good accuracy in predicting either the development of LC or HCC in the non-diabetic CHC patients. On the other hand, in diabetic patients, among all B cell subsets, CD19+CD24+CD38− primarily memory B cells showed good accuracy in predicting LC [accuracy = 90%, area under the curve (AUC) = 0.9, p > 0.0001]. The best cut-off for the prediction of LC was ≤ 23.2 (% from CD19+ B cells) with a sensitivity of 100% and specificity of 80% Fig. 4. Furthermore, Immature/transitional B cells showed moderate accuracy in prediction of LC [accuracy = 77%, AUC = 0.72, p = 0.03]. The best cut off for the prediction of LC was > 10.5 (% from CD19+ B cells) with a sensitivity of 85% and specificity of 70%.

CD19+CD24+CD38− naïve mature B cells were the only B cell subset showing good prognostic accuracy in the prediction of HCC [accuracy = 86.4%, AUC = 0.9, p = 0.006]. The best cut-off for the prediction of HCC was < 48.7 (% from CD19+ B cells) with a sensitivity of 73% and specificity of 100%, Fig. 4.

Discussion

Little is known about the changes in B cell subsets in T2D patients and CHC patients, and to date, seemingly no one has addressed the relations of B cell subsets with liver disease progression in the diabetic CHC patients. For this purpose, B cell subsets were analyzed in the peripheral blood of 67 CHC patients to avoid invasive techniques which may reflect, at least qualitatively, subset distribution in tissues such as bone marrow, lymph nodes, and liver. To verify the relation of the different B cell subsets with liver disease progression in CHC diabetic patients, we first compared the levels of the B cell subsets between the diabetic and non-diabetic patients regardless of the severity of liver affection. Finally, we compared the levels of the different B cell subsets between CHC-N, CHC-LC, and CHC-HCC patients irrespective of the presence of diabetes. In contrast, in the non-diabetic patients, although it raised in the CHC-diabetic patients, where the level of this subset was considerably elevated in the three groups of diabetic patients (CHC-N, CHC-LC, and CHC-HCC). In contrast, in the non-diabetic patients, although it raised in the CHC-diabetic patients, where the level of this subset was considerably elevated in the three groups of diabetic patients (CHC-N, CHC-LC, and CHC-HCC). In contrast, in the non-diabetic patients, although it raised in the CHC-diabetic patients, where the level of this subset was considerably elevated in the three groups of diabetic patients (CHC-N, CHC-LC, and CHC-HCC). In contrast, in the non-diabetic patients, although it raised in the CHC-diabetic patients, where the level of this subset was considerably elevated in the three groups of diabetic patients (CHC-N, CHC-LC, and CHC-HCC). In contrast, in the non-diabetic patients, although it raised in the CHC-diabetic patients, where the level of this subset was considerably elevated in the three groups of diabetic patients (CHC-N, CHC-LC, and CHC-HCC). In contrast, in the non-diabetic patients, although it raised in the CHC-diabetic patients, where the level of this subset was considerably elevated in the three groups of diabetic patients (CHC-N, CHC-LC, and CHC-HCC).
Scientific Reports | (2020) 10:20383 | https://doi.org/10.1038/s41598-020-77416-0

In the current study, regardless of the presence of diabetes, significant elevation of the CD19^+CD24^-CD38^- naive memory B cells was observed in HCV patients. This study was the first to analyze the different B cell subsets in CHC patients with T2D. Overall our results demonstrate a strong association between B cell subsets and liver disease progression in those patients. Thus the future research on these subsets might prove their value in pathogenesis, immunotherapy, and as predictors of disease progression. Still, this study has some potential limitations; none of the tested B cell subsets has shown noteworthy relation with the fasting plasma sugar level. This may be because most of the patients had controlled sugar levels at the time of sample collection. Significant correlations might have become evident if HbA1C was measured, which reflects the average level of glucose during the last 2–3 months. Another limitation was the small sample size. To yield more reliable estimates, the study needs to be done on a larger cohort of patients. Also, for a more comprehensive evaluation of B cell subsets, other fundamental markers and cytokines should be assessed including, CD27 and IL10. Lack of studies based on similar B cell subsets make it difficult to draw consistent conclusions.

**Strengths and limitations.** This study was the first to analyze the different B cell subsets in CHC patients with T2D. Overall our results demonstrate a strong association between B cell subsets and liver disease progression in those patients. Thus the future research on these subsets might prove their value in pathogenesis, immunotherapy, and as predictors of disease progression. Still, this study has some potential limitations; none of the tested B cell subsets has shown noteworthy relation with the fasting plasma sugar level. This may be because most of the patients had controlled sugar levels at the time of sample collection. Significant correlations might have become evident if HbA1C was measured, which reflects the average level of glucose during the last 2–3 months. Another limitation was the small sample size. To yield more reliable estimates, the study needs to be done on a larger cohort of patients. Also, for a more comprehensive evaluation of B cell subsets, other fundamental markers and cytokines should be assessed including, CD27 and IL10. Lack of studies based on similar B cell subsets make it difficult to draw consistent conclusions.
Conclusion

Immature/transitional B cells increase remarkably in diabetic CHC patients and might have a role in liver disease progression. Memory and naïve B cells are good potential predictors of LC and HCC in diabetic CHC patients, respectively. Further studies are needed to investigate the role of the CD19+CD24−CD38− new memory B cells in disease progression in CHC patients.

Received: 28 April 2020; Accepted: 11 November 2020 Published online: 23 November 2020

References

1. Dubuisson, J. & Cosset, F. L. Virolology and cell biology of the hepatitis C virus life cycle: an update. J. Hepatol. 61, S3–S13. https://doi.org/10.1016/j.jhep.2014.06.031 (2014).
2. Tripathi, B. K. & Srivastava, A. K. Diabetes mellitus: complications and therapeutics. Med. Sci. Monit. 12, RA130–RA147 (2006).
3. Capone, F. et al. The cytokine profile in patients with hepatocellular carcinoma and type 2 diabetes. PLoS ONE 10, e0134594 (2015).
4. Li, X., Jiao, Y., Xing, Y. & Gao, P. Diabetes mellitus and risk of hepatic fibrosis/cirrhosis. Biomed. Res. Int. 2019, 5308308. https://doi.org/10.1155/2019/5308308 (2019).
5. DeFuria, J. et al. B cells promote inflammation in obesity and type 2 diabetes through regulation of T-cell function and an inflammatory cytokine profile. Proc. Natl. Acad. Sci. 110, 5133–5138 (2013).
6. Winer, S. et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat. Med. 15, 921 (2009).
7. Winer, S. A. et al. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat. Med. 17, 610 (2011).
8. Falorni, A. et al. Autoantibody recognition of COOH-terminal epitopes of GAD65 marks the risk for insulin requirement in adult-onset diabetes mellitus. J. Clin. Endocrinol. Metab. 85, 309–316 (2000).
9. de Masson, A., Le Buane, H. & Bouaziz, J.-D. In Regulatory B Cells 45–52 (Springer, 2014).
10. Yao, Y. et al. CD23 expression on switched memory B cells bridges T-B cell interaction in allergic rhinitis. Allergy 75, 2599–2612. https://doi.org/10.1111/all.14288 (2020).
11. Czarnowicki, T. et al. Diverse activation and differentiation of multiple B-cell subsets in patients with atopic dermatitis but not in patients with psoriasis. J. Allergy Clin. Immunol. 137, 118–129 (2016).
12. Buffa, S. et al. A novel B cell population revealed by a CD38/CD24 gating strategy: CD38−CD24− B cells in centenarian offspring and elderly people. Age 35, 2009–2024 (2013).
13. Simon, Q. et al. In-depth characterization of CD24(high)/CD38(high) transitional human B cells reveals different regulatory profiles. J. Allergy Clin. Immunol. 137, 1577–1584.e1510. https://doi.org/10.1016/j.jaci.2015.09.014 (2016).
14. Blair, P. A. et al. CD19+CD24hiCD38hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 32, 129–140 (2010).
15. Bouaziz, J. D. et al. IL-10 produced by activated human B cells regulates CD4+ T-cell activation in vitro. Eur. J. Immunol. 40, 2686–2691 (2010).
16. Anolik, J. H. et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum. 56, 3044–3056 (2007).
17. Das, A. et al. IL-10–producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J. Immunol. 189, 3925–3935 (2012).
18. Moir, S. & Fauci, A. S. Insights into B cells and HIV-specific B-cell responses in HIV-infected individuals. Immunol. Rev. 254, 207–224 (2013).
19. Cuss, A. K. et al. Expansion of functionally immature transitional B cells is associated with human-immunodeficient states characterized by impaired humoral immunity. J. Immunol. 176, 1506–1516 (2006).
20. Hausfater, P. et al. Hepatitis C virus infection and lymphoproliferative diseases: prospective study on 1,576 patients in France. Am. J. Hematol. 67, 168–171 (2001).
21. Raccanelli, V. & Rehermann, B. Hepatitis C virus infection: when silence is deception. Trends Immunol. 24, 456–464 (2003).
22. Sansonno, D. & Dammacco, F. Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations. Lancet Infect. Dis. 5, 227–236 (2005).
23. Silvestri, F. et al. Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders. Blood 87, 4296–4301 (1996).
24. Zuckerman, E. et al. Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. Ann. Intern. Med. 127, 423–428 (1997).
25. Sugalski, J. M., Rodriguez, B., Moir, S. & Anthony, D. D. Peripherical blood B cell subset skewing is associated with altered cell cycling and intrinsic resistance to apoptosis and reflects a state of immune activation in chronic hepatitis C virus infection. J. Immunol. 185, 3019–3027 (2010).
26. Doi, H. et al. Dysfunctional B-cell activation in cirrhosis resulting from hepatitis C infection associated with disappearance of CD27-Positive B-cell population. Hepatology 55, 709–719 (2012).
27. American Diabetes Association (ADA). 2 Classification and diagnosis of diabetes: standards of medical care in diabetes—2018. Diabetes Care 41, 13–27 (2018).
28. Zhao, X. et al. Elevated B cell activation is associated with type 2 diabetes development in obese subjects. Cell. Physiol. Biochem. 38, 1257–1266 (2016).
29. Wang, L. et al. Increased numbers of CD5+CD19+CD1d high IL-10+ Bregs, CD4+ Foxp3+ Tregs, CD4+ CXCR5+ Foxp3+ follicular regulatory T (TFR) cells in CHB or CHC patients. J. Transl. Med. 12, 251 (2014).
30. Raccanelli, V. et al. Antibody production and in vitro behavior of CD27-defined B-cell subsets: persistent hepatitis C virus infection changes the rules. J. Virol. 80, 3923–3934 (2006).
31. Hanley, P. et al. Circulating B cells in type 1 diabetes exhibit fewer maturation-associated phenotypes. Clin. Immunol. 183, 336–343 (2017).
32. Nishimura, S. et al. Adipose natural regulatory B cells negatively control adipose tissue inflammation. Cell Metab. 18, 759–766 (2013).
33. Klett, S. et al. Interleukin-10+ regulatory B cells arise within antigen-experienced CD40+ B cells to maintain tolerance to islet autoantigens. Diabetes 64, 158–171 (2015).
34. Batten, M. et al. BAFF mediates survival of peripheral immune B lymphocytes. J. Exp. Med. 192, 1453–1466 (2000).
35. Shao, Y. et al. Regulatory B cells accelerate hepatocellular carcinoma progression via CD40/CD154 signaling pathway. Cancer Lett. 355, 264–272 (2014).
36. Hetta, H., Elkady, A., Tohamy, T. & Badary, M. Regulatory B cells: key players in hepatocellular carcinoma progression. Gastroenterol. Hepatol. Open Access 5, 00136 (2016).
37. DiLillo, D. J., Matsushita, T. & Tedder, T. F. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. *Ann. N. Y. Acad. Sci.* **1183**, 38–57 (2010).

38. Moulin, V. *et al.* B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell–deficient mice results in T helper cell type 1 deviation. *J. Exp. Med.* **192**, 475–482 (2000).

39. Fourrillier, A. *et al.* Analysis of B-lymphocyte differentiation in patients infected with hepatitis C virus. *J. Med. Virol.* **72**, 566–574 (2004).

40. Chang, L.-Y., Li, Y. & Kaplan, D. E. Endotoxemia contributes to CD27+ memory B-cell apoptosis via enhanced sensitivity to Fas ligation in patients with Cirrhosis. *Sci. Rep.* **6**, 36862 (2016).

41. Mizuochi, T. *et al.* Possible recruitment of peripheral blood CXCR3+ CD27+ CD19+ B cells to the liver of chronic hepatitis C patients. *J. Interferon Cytokine Res.* **30**, 243–252 (2010).

42. Farci, P. *et al.* Lack of protective immunity against reinfection with hepatitis C virus. *Science* **258**, 135–140 (1992).

43. Bernasconi, N. L., Traggiai, E. & Lanzavecchia, A. Maintenance of serological memory by polyclonal activation of human memory B cells. *Science* **298**, 2199–2202 (2002).

44. Fecteau, J. F. & Néron, S. CD40 stimulation of human peripheral B lymphocytes: distinct response from naive and memory cells. *J. Immunol.* **171**, 4621–4629 (2003).

45. Tangye, S. G., Avery, D. T., Deenick, E. K. & Hodgkin, P. D. Intrinsic differences in the proliferation of naive and memory human B cells as a mechanism for enhanced secondary immune responses. *J. Immunol.* **170**, 686–694 (2003).

46. Bordon, Y. B cell responses: plasmablasts walk the line. *Nat. Rev. Immunol.* **10**, 541 (2010).

47. Fink, K. Origin and function of circulating plasmablasts during acute viral infections. *Front. Immunol.* **3**, 78 (2012).

48. American Diabetes Association (ADA). Diagnosis and classification of diabetes mellitus. *Diabetes Care* **33**, 62–69 (2010).

**Acknowledgements**

We would like to express our gratitude to all technicians in the flow cytometry laboratories in the Medical Research Center and South Egypt Cancer Institute, Assiut University, for their assistance throughout the work.

**Author contributions**

All authors contributed to the study conception and design. Material preparation and data collection were accomplished by F.A.A, H.H, M.O.A, A.Z, and O.E and data analysis was performed by F.A.A, K.M.H, and O.E. The first draft of the manuscript was written by F.A.A and O.E and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

**Funding**

The authors received no specific funding for this work.

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Correspondence** and requests for materials should be addressed to O.E.-B.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020